Go Deep
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,362 | -4.8 | 3.32 | 1.80 | 1,097.09 |
| Oct 2026 | 17,511 | -4.6 | 3.22 | 1.80 | 1,061.51 |
| Oct 2026 | 17,384 | -4.9 | 3.31 | 1.80 | 1,089.20 |
| Oct 2026 | 17,546 | -4.6 | 3.20 | 1.80 | 1,051.34 |
| Oct 2026 | 17,410 | -4.7 | 3.29 | 1.80 | 1,081.85 |
| Oct 2026 | 17,297 | -4.8 | 3.36 | 1.80 | 1,106.51 |
| Oct 2026 | 17,454 | -4.7 | 3.26 | 1.80 | 1,069.72 |
| Oct 2026 | 17,319 | -4.8 | 3.35 | 1.80 | 1,096.82 |
| Oct 2026 | 17,310 | -4.8 | 3.35 | 1.80 | 1,103.26 |
Enanta Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 14,359,000.0 | 17,159,000.0 | 18,615,000.0 | 15,125,000.0 |
| Net Profit | -19,501,000.0 | -13,091,000.0 | -11,938,000.0 | -18,700,000.0 |
| EPS | -0.7 | -0.5 | -0.4 | -0.9 |
Enanta Pharmaceuticals, Inc. Revenue & Profit: Last 4 Years
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Revenue | 65,324,000.0 | 67,635,000.0 | 79,204,000.0 | 86,160,000.0 |
| Net Profit | -81,889,000.0 | -116,045,000.0 | -133,816,000.0 | -121,755,000.0 |
| EPS | -3.8 | -5.5 | -6.4 | -5.9 |
Enanta Pharmaceuticals, Inc. Balance Sheet
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Total Assets | 280,732,000.0 | 376,652,000.0 | 462,275,000.0 | 375,410,000.0 |
| Total Liabilities | 216,015,000.0 | 247,838,000.0 | 245,540,000.0 | 54,076,000.0 |
| Total Equity | 64,717,000.0 | 128,814,000.0 | 216,735,000.0 | 321,334,000.0 |
Owes vs Owns
Enanta Pharmaceuticals, Inc. owed $0.66 for every $1 it owned in Jun 2026, up from $0.14 in Sep 2022.
| Period | Jun 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.66× | 0.77× | 0.66× | 0.53× | 0.14× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Enanta Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Sep 2025
Cash & short-term investments 67.3%Receivables 2.5%Fixed assets (tangible) 26.0%Other assets 4.3%
How it's funded — Sep 2025
Short-term debt 1.1%Long-term debt 19.5%Payables 0.7%Other liabilities 55.6%Shareholders' equity 23.1%
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 188.9 | 248.2 | 369.9 | 249.2 |
| Receivables | 6.9 | 38.6 | 39.6 | 49.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 72.9 | 73.3 | 34.7 | 29.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 29.3 |
| Other assets | 12.0 | 16.5 | 18.0 | 18.1 |
| Liabilities & equity | ||||
| Short-term debt | 3.1 | 1.5 | 5.3 | 2.9 |
| Long-term debt | 54.8 | 53.9 | 21.2 | 22.4 |
| Payables | 1.9 | 8.0 | 4.1 | 6.0 |
| Other liabilities | 156.2 | 184.4 | 214.9 | 22.8 |
| Shareholders' equity | 64.7 | 128.8 | 216.7 | 321.3 |
| Net tangible assets | 64.7 | 128.8 | 216.7 | 321.3 |
Enanta Pharmaceuticals, Inc. Cash Flow
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Operating Activities | -19,272,000.0 | -78,764,000.0 | -103,154,000.0 | -84,782,000.0 |
| Investing Activities | 40,347,000.0 | 58,235,000.0 | -53,578,000.0 | 54,897,000.0 |
| Financing Activities | -26,618,000.0 | -27,626,000.0 | 198,126,000.0 | 20,033,000.0 |